Augmentin 1G(875+125) GSK
Home/Store/BCX-i Pharmacy ဆေးနှင့်ဆေးပစ္စည်များ/ကိုဗစ် ကာကွယ်ကုသရေး ဆေးနှင့် ဆေးပစ္စည်းကိရိယာများ COVID-19 medicine and health products
Ks20,000.00
Sold out
Selling by
Product Details
ပဋိဇီဝ ပိုးသတ်ဆေး ဆရာဝန်ညွှန်ကြားချက်ဖြင့်သာသောက်ရန်
Contents
Co-amoxiclav: Amoxicillin, potassium clavulanate.
Description
Augmentin: Tablet: Each tablet contains amoxicillin 875 mg (as amoxicillin trihydrate) and 125 mg clavulanic acid (as potassium clavulanate).
Each 5 mL of 156-mg reconstituted TID suspension contains amoxicillin 125 mg (as amoxicillin trihydrate) and clavulanic acid 31.25 (as potassium clavulanate).
Excipients/Inactive Ingredients: Augmentin: Tablet: Magnesium stearate, sodium starch gylcolate, colloidal silica, microcrystalline cellulose, titanium dioxide (E171), hydroxypropyl methylcellulose, polyethylene glycol and silicone oil.
TID suspension: Xanthan gum, hydoxypropylmethylcellulose, aspartame, silicon dioxide, colloidal silica, succinic acid, raspberry, orange and golden syrup dry flavours.
Augmentin ES: Colloidal silicon dioxide, sodium carboxymethylcellulose-12, strawberry cream flavour, xanthan gum, aspartame and silicon dioxide.
Augmentin SR: Tablet Core: Microcrystalline cellulose PhEUR/NF, sodium starch gylcolate BP/NF, colloidal silicon dioxide NF, magnesium stearate PhEUR/NF, xanthan gum NF, citric acid NF. Film-Coat (Opadry YS 1 7700): Hydroxypropylmethylcellulose 2910 6cp PhEUR/USP, hydroxypropylmethylcellulose 2910 15cp PhEUR/USP, titanium dioxide PhEUR/USP, polyethylene glycol 3350 USNF, polyethylene glycol 8000 USNF.
Augmentin presentations do not contain sucrose, tartrazine or any azo dyes and Augmentin suspensions do not contain preservatives.
Augmentin ES: Each 5-mL suspension contains amoxicillin 600 mg (as amoxicillin trihydrate) and clavulanic acid 42.9 mg (as potassium clavulanate), a 14:1 ratio.
Augmentin SR: Each tablet contains amoxicillin 1062.5-mg (562.5 mg as amoxicillin trihydrate and 437.5 mg amoxicillin sodium) and clavulanic acid 62.5 mg (as potassium clavulanate), a 16:1 ratio.
Each 5 mL of 156-mg reconstituted TID suspension contains amoxicillin 125 mg (as amoxicillin trihydrate) and clavulanic acid 31.25 (as potassium clavulanate).
Excipients/Inactive Ingredients: Augmentin: Tablet: Magnesium stearate, sodium starch gylcolate, colloidal silica, microcrystalline cellulose, titanium dioxide (E171), hydroxypropyl methylcellulose, polyethylene glycol and silicone oil.
TID suspension: Xanthan gum, hydoxypropylmethylcellulose, aspartame, silicon dioxide, colloidal silica, succinic acid, raspberry, orange and golden syrup dry flavours.
Augmentin ES: Colloidal silicon dioxide, sodium carboxymethylcellulose-12, strawberry cream flavour, xanthan gum, aspartame and silicon dioxide.
Augmentin SR: Tablet Core: Microcrystalline cellulose PhEUR/NF, sodium starch gylcolate BP/NF, colloidal silicon dioxide NF, magnesium stearate PhEUR/NF, xanthan gum NF, citric acid NF. Film-Coat (Opadry YS 1 7700): Hydroxypropylmethylcellulose 2910 6cp PhEUR/USP, hydroxypropylmethylcellulose 2910 15cp PhEUR/USP, titanium dioxide PhEUR/USP, polyethylene glycol 3350 USNF, polyethylene glycol 8000 USNF.
Augmentin presentations do not contain sucrose, tartrazine or any azo dyes and Augmentin suspensions do not contain preservatives.
Augmentin ES: Each 5-mL suspension contains amoxicillin 600 mg (as amoxicillin trihydrate) and clavulanic acid 42.9 mg (as potassium clavulanate), a 14:1 ratio.
Augmentin SR: Each tablet contains amoxicillin 1062.5-mg (562.5 mg as amoxicillin trihydrate and 437.5 mg amoxicillin sodium) and clavulanic acid 62.5 mg (as potassium clavulanate), a 16:1 ratio.
Action
Pharmacology: Pharmacodynamics: Augmentin: 1 g: Resistance to many antibiotics is caused by bacterial enzymes which destroy the antibiotic before it can act on the pathogen. The clavulanate in Augmentin anticipates this defence mechanism by blocking the ß-lactamase enzymes, thus rendering the high concentration of Amoxicillin effected on bactericidal in the body.
Clavulanate by itself has little antibacterial activity; however, in association with amoxicillin as Augmentin, it can be antibiotic agent of bacterial resistant Amoxicillin by producing β-lactamase for destroying. It can be treated the bacterial infection in with wide application in hospital and general practice.
In the list as follows, organisms are categorised according to their in vitro susceptibility to Augmentin. (See Table 1.)
Augmentin/Augmentin ES/Augmentin SR: Mechanism of Action: Amoxicillin is a semisynthetic antibiotic with a broad-spectrum antibacterial activity against many gram-positive and gram-negative microorganisms. Amoxicillin is, however, susceptible to degradation by β-lactamases and therefore, the spectrum of activity of amoxicillin alone does not include organisms which produce these enzymes.
Clavulanic acid/clavulanate is a β-lactam, structurally related to the penicillins, which possesses the ability to inactivate a wide range of β-lactamase enzymes commonly found in microorganisms resistant to penicillins and cephalosporins. In particular, it has a good activity against the clinically important plasmid-mediated β-lactamases frequently responsible for transferred drug resistance. It is generally less effective against chromosomally-mediated type 1 β-lactamases.
The presence of clavulanic acid in Augmentin/ES/SR protects amoxicillin from degradation by β-lactamase enzymes and effectively extends the antibacterial spectrum of amoxicillin to include many bacteria normally resistant to amoxicillin, cephalophorins and other β-lactam antibiotics. Thus, Augmentin/ES/SR possesses the distinctive properties of a broad-spectrum antibiotic and a β-lactamase inhibitor.
Resistance to many antibiotics is caused by bacterial enzymes which destroy the antibiotic before it can act on the pathogen. The clavulanate in Augmentin/ES/SR anticipates this defense mechanism by blocking the β-lactamase enzymes, thus rendering the organisms susceptible to amoxicillin's rapid bactericidal effect at concentrations readily attainable in the body.
Clavulanate by itself has little antibacterial activity; however, in association with amoxicillin as Augmentin/ES/SR, it produces an antibiotic agent of broad spectrum with wide application in hospital and general practice.
Other Information: Cross-Resistance: Amoxicillin on its own shows cross-resistance to other β-lactams, β-lactam/β-lactamase inhibitor combinations and cephalosporins.
Resistance Mechanism: Clavulanate protects against resistance mediated by certain β-lactamase enzymes. The sustained-release formulation of Augmentin SR improves efficacy against organisms with resistance mediated by modified penicillin-binding proteins (PBPs).
Clavulanate by itself has little antibacterial activity; however, in association with amoxicillin as Augmentin, it can be antibiotic agent of bacterial resistant Amoxicillin by producing β-lactamase for destroying. It can be treated the bacterial infection in with wide application in hospital and general practice.
In the list as follows, organisms are categorised according to their in vitro susceptibility to Augmentin. (See Table 1.)
Augmentin/Augmentin ES/Augmentin SR: Mechanism of Action: Amoxicillin is a semisynthetic antibiotic with a broad-spectrum antibacterial activity against many gram-positive and gram-negative microorganisms. Amoxicillin is, however, susceptible to degradation by β-lactamases and therefore, the spectrum of activity of amoxicillin alone does not include organisms which produce these enzymes.
Clavulanic acid/clavulanate is a β-lactam, structurally related to the penicillins, which possesses the ability to inactivate a wide range of β-lactamase enzymes commonly found in microorganisms resistant to penicillins and cephalosporins. In particular, it has a good activity against the clinically important plasmid-mediated β-lactamases frequently responsible for transferred drug resistance. It is generally less effective against chromosomally-mediated type 1 β-lactamases.
The presence of clavulanic acid in Augmentin/ES/SR protects amoxicillin from degradation by β-lactamase enzymes and effectively extends the antibacterial spectrum of amoxicillin to include many bacteria normally resistant to amoxicillin, cephalophorins and other β-lactam antibiotics. Thus, Augmentin/ES/SR possesses the distinctive properties of a broad-spectrum antibiotic and a β-lactamase inhibitor.
Resistance to many antibiotics is caused by bacterial enzymes which destroy the antibiotic before it can act on the pathogen. The clavulanate in Augmentin/ES/SR anticipates this defense mechanism by blocking the β-lactamase enzymes, thus rendering the organisms susceptible to amoxicillin's rapid bactericidal effect at concentrations readily attainable in the body.
Clavulanate by itself has little antibacterial activity; however, in association with amoxicillin as Augmentin/ES/SR, it produces an antibiotic agent of broad spectrum with wide application in hospital and general practice.
Other Information: Cross-Resistance: Amoxicillin on its own shows cross-resistance to other β-lactams, β-lactam/β-lactamase inhibitor combinations and cephalosporins.
Resistance Mechanism: Clavulanate protects against resistance mediated by certain β-lactamase enzymes. The sustained-release formulation of Augmentin SR improves efficacy against organisms with resistance mediated by modified penicillin-binding proteins (PBPs).
Display prices in:MMK